Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Press Announcements

Press Announcements Home
          News & Events
          FDA Newsroom
          Press Announcements
          FDA Roundup: January 19, 2024Press Announcements FDA News Release
  FDA Roundup: January 19, 2024

  
  Share
    Post
    Linkedin

    Email
    PrintFor Immediate Release:
                  January 19, 2024
 

  
      
       

  Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:

Today, the FDA issued marketing denial orders (MDOs) to Shenzhen Youme Information Technology Co. Ltd. for two Suorin brand e-cigarette products and to Fontem US, LLC for blu PLUS+ brand e-cigarette products. The companies must not market or distribute these products in the United States or they risk FDA enforcement action.
	On Thursday, the FDA and the Centers for Medicare & Medicaid Services (CMS) issued a joint statement reiterating mutual support of the FDA’s oversight of laboratory developed tests (LDTs), including the analytical and clinical validity of these tests. LDTs help physicians make critical decisions about their patients’ care. According to the Centers for Disease Control and Prevention, approximately 70% of health care decisions depend on laboratory test results. Because of the important role of laboratory tests in health care decisions, it is essential to ensure these tests work. Both the FDA and the CMS believe patients and providers need to have confidence that laboratory tests work.
	On Thursday, the FDA issued a safety communication to alert patients, caregivers, and health care providers about certain recalled ResMed Ltd (ResMed) masks used with bilevel positive airway pressure (also known as Bilevel PAP, BiPAP, or BPAP) machines and continuous positive airway pressure (CPAP) machines. These recalled masks have magnets that can cause potential injuries or death when the magnets interfere with certain implanted metallic medical devices or metallic objects in the body. These potential adverse events can occur in people who use the masks or in people near a person using the mask. Additionally, the recalled ResMed masks may be used with other manufacturers’ BiPAP and CPAP machines. Users of any BiPAP or CPAP machine should check to see if their mask is one of the recalled ResMed masks.
	On Wednesday, the FDA issued a Safety Alert advising restaurants and retailers not to serve or sell and consumers not to eat certain oysters from Baja California, Mexico potentially contaminated with norovirus.
	On Wednesday, the FDA’s Center for Devices and Radiological Health (CDRH) issued its 2023 Annual Report. 2023 was a transformative year for CDRH. The Center officially turned a corner on the COVID-19 pandemic and moved toward a more sustainable workload, including prioritizing normal review timelines for all incoming premarket submissions. In 2023, CDRH authorized the highest number of novel medical devices on record (excluding EUAs). In addition to highlighting medical device authorizations, the 2023 Annual Report illustrates the many ways CDRH continues to advance innovation and ensure people have access to safe, effective, and high-quality medical devices and radiation-emitting products.
	On Wednesday, the FDA announced that Emergent Biosciences will extend the shelf-life of Narcan 4 milligram (mg) naloxone hydrochloride nasal spray products from 3-years to 4-years. The extension request is the latest of multiple steps that the FDA has taken to reduce overdose-related deaths.
	On Tuesday, the FDA issued marketing denial orders (MDOs) to Shenzhen IVPS Technology Co., Ltd for 22 SMOK brand e-cigarette products. The denied products include devices, pods, atomizers, and cartridges, which are part of an e-cigarette system marketed without an e-liquid. The company must not market or distribute these products in the United States or they risk FDA enforcement action.
	On Tuesday, the FDA alerted patients and health care providers about health risks associated with the Equinoxe Shoulder System joint replacement devices. These devices were manufactured by Exactech between 2004 and August 2021 and were packaged in defective bags. The defective bags were missing one of the oxygen barrier layers that protect the devices from oxidation, a chemical reaction with oxygen that can degrade plastics over time. Oxidation can lead to faster device wear or failure, and device component cracking or fracture. These issues could lead people with the device to need additional surgery to replace or correct the implanted Equinoxe Shoulder System. The FDA issued a safety communication on March 23, 2023, about a similar issue with other Exactech joint replacement devices.Related Information
  
  Related Information
              FDA Newsroom

###
  Boilerplate
      The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Inquiries
  
    
        
         Media:
                 
      
                            FDA Office of Media Affairs
           
           
                      888-INFO-FDA
    Consumer:
                        888-INFO-FDA

                                                                                  Content current as of:
      01/19/2024
               
               
Regulated Product(s)
		 Biologics
			  			     			  			     Drugs
			     			  			     Medical Devices   

        Follow FDA
            Follow @US_FDAon X
                Follow FDAon Facebook
                Follow @FDAMediaon XMore Press Announcements
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop